CORE Summit is the only venue dedicated to outcomes research and comparative effectiveness research in China. This event provides an unique platform for sponsors to interacting with the stake holders from government, medical community, academic and research organizations. It  represents an  opportunity for sponsors to demonstrate and solidify their commitment and leadership in evidence based medicine and marketing in China and on a global scale.

The current challenges and opportunities may be summarized in the bullets below:·      

• Real world medical evidence is being increasingly valued for pricing and market access;
  
• Government and third party payers demand for comparative effectiveness evidence;
• Physicians and medical opinion leaders are driving evidence based practice;
• Significant gaps between guidelines and practice represents unmet needs.

 

At the 2011 CORE Summit, there were 10 sponsors and exhibitors as shown below:

No. of Sponsors & Exhibitors	No. of Attendees	No. of Organization	No. of Speakers	No. of Media
10	268	18	31	3

                                                

  2011 CORE Summit attendance distribution is shown in the graph below:

     

              

2012 CORE Summit Unique Features:

• Keynote speakers include world top tier leaders and experts on outcomes research, comparative effectiveness research and value based health care and medicine;
• Attending physicians receive CME credits administrated by CMDA;
• Government and third party payers support and are interested in the topics
• Medical experts will present landscape outcomes research conducted in China
• Physicians and researchers have the opportunity to present their real world studies
  
• Both global and domestic organizations are expected to sponsor and exhibit
  

2012 CORE Summit Sponsor’s Benefits:

1. Sponsor's banner may be posted on the conference site;
2. Sponsor's logo may be printed on the program and posted on the CORE website;
   
3. Sponsor may insert up to one page of statement or advertisement in the program;
4. Sponsor may insert a logo or a paragraph of statement on VitalHealth Newsletter;
   
5. Sponsor may be provided with an exhibition space;
6. Sponsor may have free registration for up to four registrants;

Sponsorship & Exhibition Options:

• Gold conference sponsor - $10,000
• Receive the sponsor's benefits  #1-#6 (banner and logo display, one page ad in program, logo and statement in VitalHealth, one exhibition space, 2 free meeting registration)
• Receive a session speaking opportunity 

• Special session sponsor - $5,000

• Receiving the sponsor's benefits #2-#4 (logo display, half page ad in program, logo and statement in VitalHealth)
• Receiving a session speaking opportunity and one free registration

About Medidata Solutions Worlwide

Sanofi Pasteur, the vaccines division of Sanofi-Aventis, is a worldwide leader of vaccines. Sanofi Pasteur has a broad portfolio to meet pediatric and adult immunization requirements in China.

In January 2010, Sanofi-Aventis signed agreements with Hangzhou Minsheng Pharmaceutical Co., Ltd to form a new consumer healthcare joint venture. Sanofi-Aventis made its first strategic entry into the dynamic CHC Market, especially in VMS segment.

In Feb 2011, Sanofi-Aventis finished the acquisition of BMP Sunstone in China. This embarks on a new milestone of our global vision that is to become a diversified healthcare leader. The transaction accelerates Sanofi-Aventis’ consumer healthcare business in the Cough & Cold and Women’s health segments.

Sanofi-Aventis is engaged in integrated R&D in China from drug target identification to late stage clinical studies. Its China R&D Center and Asia Pacific R&D Center are based in Shanghai, supported by branches in Beijing and Chengdu.

 United BioSource Corporation (UBC), a wholly owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS), is a global scientific and medical affairs organization that partners with life science companies to make medicine and medical products smarter for all stakeholders in the health care landscape.  UBC helps deliver authoritative, real-world evidence to characterize product effectiveness, address safety risk, and demonstrate value. UBC brings together recognized scientific and industry experts, research operations professionals, and new technologies to provide innovative solutions across the product lifecycle.  The company is headquartered in Chevy Chase, MD with offices in North and South America, Europe and Asia.  UBC has a team of more than 2,200 professionals at 32 sites in nine countries dedicated to specialty services that leverage science, innovation, and technology. More than 30 percent of UBC employees hold advanced scientific degrees, and employee turnover is less than 10 percent. UBC is currently working with more than 375 clients worldwide.  For more information about UBC, visit www.unitedbiosource.com.

Innovus, HTanalysts, QualityMetric, ChinaGate, CanReg and Ingenix are now OptumInsight—part of Optum, a leading health services business. OptumInsight provides an expert perspective on global market requirements to help companies make strategic decisions about their products. With leading expertise in health economics and outcomes research, late phase research, epidemiology, and market access and reimbursement, OptumInsight develops and implements strategic study designs that combine scientific, regulatory and commercial objectives to help maximize opportunities for its clients’ products in the marketplace. Look to OptumInsight for an expanded range of life sciences capabilities in the Asia-Pacific region geared to help you demonstrate your products’ value, improve product lifecycle efficiency, and gain greater competitive advantage.

Striving toward better health for individuals and progress in medicine.

As a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Takeda Global Research & Development Center, Inc. (TGRD) has a robust pipeline of compounds in multiple therapeutic areas including diabetes, cardiovascular disease, neuroscience, and gastroenterology. Takeda’s U.S. commercial activities are conducted via Takeda Pharmaceuticals U.S.A., Inc. (TPUSA), one of the top 15 pharmaceutical companies in the United States. TPUSA was founded in 1998 to accelerate Takeda's global expansion into the U.S. market. Improving the lives of patients is at the center of everything we do. Takeda is enjoying tremendous growth as an emerging global leader in the pharmaceutical industry, but we remain ever mindful of our commitment to serve patients by striving toward better health for patients worldwide through leading innovation in medicine. The spirit of our commitment extends to our employees, partners and the larger community

Shaping a Path to Discovery

TGRD dedicates its resources to the Takeda product pipeline in an effort to deliver innovative medicines to patients. As a research-based pharmaceutical company efforts are currently focused on pre-clinical work and clinical development activities in the United States.  Our commitment to bringing superior pharmaceutical products to market is enhanced by our close strategic relationship with the entire Takeda family of companies. Collaborating in the earliest stages of a compound’s development ensures effective product lifecycle management and sensitivity to patient needs.  fforts are currently focused on the research and development of new treatments for diabetes, insomnia, cardiovascular disease, and gastrointestinal disorders. The Takeda family of companies works in tandem to explore new areas of medicine and bring the power of next generation science to bear in existing health conditions. Our collaborative partners adhere to Good Clinical Practices (GCP), federal requirements, and international guidelines in conducting clinical trials to protect the rights and welfare of our study participants and the validity of the study data. We have adopted the Pharmaceutical Research and Manufacturers of America (PhRMA) code of integrity, compliance, and social responsibility. We also follow Good Manufacturing and Good Laboratory Practices (GMP and GLP).

STATinMED Research is a health care consultant company providing research and consulting to global pharmaceutical, biotechnology and health information companies. To help you understand market opportunities, optimal positioning and value for your products, we provide (1) retrospective or prospective research from tabular format to advanced multivariate statistical modeling; (2) consultant services on data development, determining sample sizes and power requirements; (3) recommendation for methods and approaches to solve a particular problem; (4) statistical reports for both technical and non-technical audiences; (5) literature review and synthesis; (6) litigation reports; (7) proprietary algorithms ProbChoiceTM, SIFRATM, CompScoreTM, SESTM, NatWTM, SampSizeTM; (8) META analysis; (9) medical writing; (10) chart abstraction; (11) educational seminars; and (12) ADataViZTM: An analytic-based data visualization tool developed by STATinMED Research.
All senior managers hold academic positions with prestigious universities, bringing a unique blend of corporate experience and academic credibility to our projects. A typical project team includes professional consultants and faculty members with expertise in Health Economics, Statistics, Biostatistics, Epidemiology and Applied Mathematics with support staff of experienced analysts, research assistants and programmers. Combined, we have over 300 peer-reviewed publications and presentations, and are often invited to referee high ranked peer-review journals. Our research was awarded in 2005, 2006 and 2010, and our innovative research solutions created proprietary algorithms. Established in 2007, our headquarters are located in Ann Arbor, Michigan. In 2010, we opened two more offices in New York, NY and Dallas, TX. In 2011, STATinMED Research expanded internationally with offices in Beijing, China and Istanbul, Turkey.

•       Shanghai Centennial Scientific Ltd. is a premium health economic and health care consulting company in China established by top specialists including health economists, outcomes researchers, statisticians, clinicians, regulatory and safety/risk management professionals.Shanghai Centennial Scientific’s key deliverables and core capacities include:
•  Health Economic Evaluation, •  Health technology Assessment •  Outcomes Researches •  Market Access strategy formulation •  Pricing and reimbursement research •  Clinical trial and data   management and statistical analysis  •  Regulatory affairs •  Epidemiology research, safety and risk management •  Literature review, synthesis, and KOL survey
•    Shanghai Centennial Scientific offers above professional consulting services throughout the product lifecycle to global and local pharmaceutical/medical device companies.
•    Shanghai Centennial Scientific’s highly specialized team consists of top experts in health economists, market access, regulatory affairs, medical writing, clinical trial and data management, as well as database and multimedia experts. Our scientific team has a thorough understanding of Asia, US, European and other emerging market health care systems. The company is also closely connected with other global health economic companies to facilitate our global presence.
•    In addition to our core scientific team, we have an affiliated international scientific board comprised with a group of globally recognized experts in the area of health economics, biostatistics, policy research, market access/HTA, and graphics designing to support us on an as-needed basis
•    Shanghai Centennial Scientific bring knowledge, creativity and intellect to every project we undertake whether it is health economics, systematic review, HTA, regulatory affairs, safety assessment, or market access

BioonGroup was established since 2001. Now it has become the first Chinese media platform and professional service provider of biological medicine industry. Relying on the Internet, BioonGroup can provide consulting research, industry analysis, brand packaging, product promotion, human resources，conference planning and comprehensive service system for enterprises, research and development institutions, universities, parks and the government of biological medicine industry. BioonGroup contains six websites( www.bioon.com, www.bioon.com.cn, www.pharmon.com.cn， www.bioonjob.com, www.bioinsight.com.cn， www.bioevent.cn)and core database of biological medicine industry, so we can provide the leading, accurate, efficient service systems and solutions.

Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most multinational pharmaceutical companies, leading CROs, investment banks and consulting firms active in China as well as relevant industry associations and government agencies. Hundreds of subscribers and over 2,000 basic members of Pharma China are mostly pharmaceutical executives with China interest or responsibility who are based in Asian, North American and European countries.

In China, Pharma China is now exclusively distributed through Beijing Jicai Pharmaceutical Technology Development Ltd.